PWP
MRNA icon

Perfromance Wealth Partners’s Moderna MRNA Stock Holding History

Perfromance Wealth Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,000
Closed -$238K – 201
2024
Q2 		$238K Buy
+2,000
New +$253K 0.01% 139
2023
Q2 		– Sell
-1,509
Closed -$232K – 189
2023
Q1 		$232K Sell
1,509
-1,101
-42% -$182K 0.01% 161
2022
Q4 		$469K Buy
2,610
+400
+18% +$65.4K 0.03% 106
2022
Q3 		$261K Sell
2,210
-700
-24% -$106K 0.02% 131
2022
Q2 		$416K Hold
2,910
– – 0.02% 107
2022
Q1 		$501K Buy
2,910
+1,200
+70% +$202K 0.02% 108
2021
Q4 		$434K Buy
+1,710
New +$500K 0.02% 123

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perfromance Wealth Partners's MRNA Position: Q3 2024 in Review

Perfromance Wealth Partners sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,000 shares — an estimated $238K sold.

Perfromance Wealth Partners first reported a position in MRNA in Q4 2021 and held it in 7 quarters. The position peaked at $501K in Q1 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Perfromance Wealth Partners reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Perfromance Wealth Partners sold 2,000 Moderna shares in Q3 2024, an estimated $238K.
  • Perfromance Wealth Partners first reported a position in Moderna in Q4 2021 and held it in 7 quarters.
  • Perfromance Wealth Partners's Moderna position peaked at $501K in Q1 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Perfromance Wealth Partners's 13F filing for Q3 2024, filed 10 Oct 2024.